| In silico design | Stable molecule | Formulation development | Market launch |
|---|
| FGF2 for cultivation media | FGF2-STAB® (patent WO2017089016A1) |
Global distribution agreement Global license agreement |
| FGF2 for cosmetics | FGF2-STAB® (patent WO2017089016A1) |
Licensing partners sought |
| FGF2 for veterinary medicine | FGF2-STAB® (patent WO2017089016A1) |
Licensing partners sought |
| FGF2 for wound healing | FGF2-STAB® (patent WO2017089016A1) |
Preclinical testing stage Licensing partners sought |
| FGF10 for cultivation media | Preparation for market entry |
| FGF10 for lung injury/disease treatment (ALI/ARDS) |
Preclinical testing stage Licensing partners sought |
| FGF7 for cell cultivation media |
Test samples on request Licensing partners sought |
| FGF18 for osteoarthritis treatment |
Test samples on request Licensing partners sought |
| FGF20 for metabolic disease treatment (obesity and diabetes) |
Test samples on request Licensing partners sought |
| FGF21 for neurodegenerative disease treatment (AD and PD) |
Test samples on request Licensing partners sought |
| Other FGFs for cell culture and medical use | FGFx (3 new molecules) |
Our molecules are being developed with a support of:
